DERM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
17.8M
+11.8%
16.0M
-0.7%
16.1M
-5.6%
17.0M
+13.4%
15.0M
Cost of Revenue
6.1M
-1.2%
6.2M
+14.3%
5.4M
-5.5%
5.8M
+16.5%
4.9M
Gross Profit
11.7M
+20.0%
9.7M
-8.3%
10.6M
-5.7%
11.3M
+11.9%
10.1M
Operating Expenses
11.9M
+6.0%
11.2M
+1.4%
11.1M
-17.3%
13.4M
+3.5%
12.9M
R&D
54.0K
0
-100.0%
154.0K
-46.3%
287.0K
0
SG&A
10.9M
+7.7%
10.1M
+2.5%
9.9M
-18.2%
12.1M
+1.4%
11.9M
Operating Income
-215000
+85.6%
-1492000
-227.2%
-456000
+78.6%
-2135000
+25.8%
-2876000
EBITDA
754.0K
+306.0%
-366000
-160.1%
609.0K
+156.9%
-1071000
+40.9%
-1812000
Net Income
-312000
+86.0%
-2230000
-78.8%
-1247000
+46.1%
-2315000
+39.0%
-3796000
EPS (Basic)
$-0.01
+87.5%
$-0.08
-60.0%
$-0.05
+44.4%
$-0.09
+43.8%
$-0.16
EPS (Diluted)
$-0.01
+87.5%
$-0.08
-60.0%
$-0.05
+44.4%
$-0.09
+43.8%
$-0.16
Shares (Diluted)
27.5M
+0.7%
27.3M
+0.6%
27.1M
+8.7%
25.0M
+7.2%
23.3M
Journey Medical (DERM) โ€” Financials